Skip to Main Content

Paper Details

Targeting the MYCN-PARP-DNA Damage Response Pathway in Neuroendocrine Prostate Cancer.
Clin Cancer Res
70
2018
-2b4, 13C, AURKA, Adeno, BRCA1, BRCA1si, C4, C4-2b4, CRPC, CRPC-, CRPC-Neuro RNA sequence data, DDR, DDR gene targets, DDR pathway genes, MDACC PDX144-, MYCN, MYCNsi, N-MYC, NCI-H660 cells, NED, NEPC, Neuro models, Neuroendocrine Prostate Cancer, PARP, PARP1, PARP2, PARPsi, PDX models, PHA739358, RMI2, RMI2si, TOPBP1, adenocarcinoma, castration-resistant prostate cancer, neuroendocrine prostate cancer, olaparib, promoters, tumor
Author NameAffiliation
Wei ZhangThe University of Texas MD Anderson Cancer Center
Wei ZhangChanghai Hospital, Second Military Medical University
Wei ZhangThe University of Texas MD Anderson Cancer Center
Wei ZhangChanghai Hospital, Second Military Medical University
Abul Kalam AzadThe University of Texas MD Anderson Cancer Center
Xuhong CaoMichigan Center for Translational Pathology, Howard Hughes Medical Institute, Comprehensive Cancer Center, University of Michigan Medical School ann arbor
Arul M ChinnaiyanMichigan Center for Translational Pathology, Howard Hughes Medical Institute, Comprehensive Cancer Center, University of Michigan Medical School ann arbor
Arul M ChinnaiyanMichigan Center for Translational Pathology, Howard Hughes Medical Institute, Comprehensive Cancer Center, University of Michigan Medical School ann arbor
Nora M NavoneThe University of Texas MD Anderson Cancer Center
  • 1 - 9

Datasets

Release 1.2